The Q(u)ALYfying Hand: Health Economics and Medicine in the Shaping of Swedish Markets for Subsidized Pharmaceuticals

Ashmore M. Mulkay M. and Pinch T. J. (1989), Health and efficiency: A sociology of health economics. Milton Keynes: Open University Press.

Berg M. (1997), Rationalizing medical work: Decision-support techniques and medical practices. Cambridge (Massachusetts): MIT Press.

Bowker G. C. and Star S. L. (1999), Sorting things out: Classification and its consequences. Cambridge (Massachusetts): MIT Press.

Callon M. (1998), ‘Introduction: The embeddedness of economic markets in economics’, in Callon M. (ed.), The laws of the markets. Oxford: Blackwell.

Callon M. Méadel C. and Rabeharisoa V. (2002), ‘The economy of qualities’, Economy and Society, 31(2): 194–217.

Callon M. and Muniesa F. (2005), ‘Economic markets as calculative collective devices’, Organization Studies, 26(8): 1229–1250.

Drummond M. F. O'Brien B. Stoddart G. L. , and Torrance G. W. (1997), Methods for the economic evaluation of health care programmes. Oxford: Oxford University Press.

Greer A. L. Goodwin J. S. Freeman J. L. and Wu Z. H. (2002), ‘Bringing the patient back in: Guidelines, practice variations, and the social context of medical practice’, International Journal of Technological Assessment in Health Care, 18(4): 747–761.

Haraway D. (1991), ‘Situated knowledges: The science question in feminism and the privilege of partial perspective’, in Haraway D. (ed.), Simians, cyborgs, and women: The reinvention of nature. London: Free Association Books.

Helgesson C.-F. Kjellberg H. and Liljenberg A. (eds) (2004), Den där marknaden: Utbyten, normer och bilder. Lund: Studentlitteratur.

Hellström P. M. and Vitols S. (2003), ‘All proton pump inhibitors are equally efficacious in standard dosages’, Läkartidningen, 100(25): 2212–2216.

Hesse M. 1974. The structure of scientific inference. London: Mac Millan.

Holm P. (2003), ‘Which way is up on Callon?’, Sociologisk årbok, 8(1): 125–156.

Junker S. (2003), ‘Ett läkemedels öde: Dumpning i en politisk soptunna’, working paper, Score Working Papers, 2003-2.

Keating P. and Cambrosio A. (2003), Biomedical platforms: Realigning the normal and the pathological in late-twentieth-century medicine. Cambridge (Massachusetts): MIT Press.

Kjellberg H. and Helgesson C-F. (2006), ‘Multiple versions of markets: Multiplicity and performativity in market practice’, Industrial Marketing Management, 35(7): 839–855.

Lagrelius A.-M. (2004), ‘The Trojan Horse: On guidelines, clinical practice and the translation of responsibility’, 4S/EASST Conference, Paris (France), 25–28 August.

Law J. (2002a), Aircraft stories: Decentering the object in technoscience. Durham: Duke University Press.

Law J. (2002b), ‘Economics as interference’, in du Gay P. and Pryke M. (eds.), Cultural economy: Cultural analysis and commercial life. London: Sage.

LFN (the PharMaceutical Benefits Board) (2002), ‘Informationsbroschyr: Ansvarsområden och arbetsuppgifter’. Public information broschure.

LFN (2003a), ‘Arbetsordning’. Reference no. 412/2002. Documentation of formal work processes.

LFN (2003b), ‘Arbetsplan för den inledande fasen av genomgà6ngen av läkemedelsortimentet’. Reference no. 1023/2003. Documentation of formal work plan for product assortment review.

LFN (2003c) ‘LFN provar subvention av 2000 läkemedel’. Issued 2003-10-21. Press release.

LFN (2003d), ‘Villkorat bifall Xenical’. Issued 2003-06-04. Decision justification document.

LFN (2003e), ‘Företag och läkemedel – genomgången av medel vid syrarelaterad symtom’. Issued 2003-10-23. Documentation of drugs included in therapy group.

LFN (2003f), ‘Avslag för Aunativ’. Issued 2003-01-30. Decision justification document.

LFN (2003g), ‘Avslag för Robinul’. Issued 2003-01-30. Decision justification document.

LFN (2005), ‘Slutrapport: Genomgången av läkemedel mot migrän’. Issued 2005-02-18. Final report for product assortment review of therapy group.

LFN (2006), ‘Slutrapport: Genomgången av läkemedel mot sjukdomar orsakade av magsyra’. Issued 2006-01-19. Final report for product assortment review of therapy group.

Levitt T. (1960), ‘Marketing myopia’, Harvard Business Review, 38(4): 45–56.

MacKenzie D. Muniesa F. and Siu L. (eds.) (2007), Do economists make markets? On the performativity of economics. Princeton: Princeton University Press.

Mol A. (1999), ‘Ontological politics: A word and some questions’, in Law J. and Hassard J. (eds.), Actor network theory and after. Oxford: Blackwell.

Mol A. (2002), The body multiple: Ontology in medical practice. Durham: Duke University Press.

New Pharmaceutical Benefits Bill (2001), ref. no. 2001/02:63. Submitted 2001-12-13.

Nord E. (1999), Cost-value analysis in health care: Making sense out of QALYs. Cambridge: Cambridge University Press.

östman J. Agenäs I. Brun J. Elwin C-E Engstrand L. Johansson S. Lindberg G. Maké L-å Norlund A. Nyrén O. Seensalu R. Sjölund K. Svensson å. Wallmark J. and Werkö L. (2000), ‘Ont i magen – metoder för diagnos och behandling av dyspepsi’. Stockholm: SBU Yellow Book.

Rappert B. (2001), ‘The distribution and resolution of the ambiguities of technology, or why Bobby can't spray’, Social Studies of Science, 31(4): 557–591.

Scherer F. M. and Ross D. (1990), Industrial market structure and economic performance. Boston: Houghton Mifflin.

Serres M. (1972), L'interférence. Paris: Editions de Minuit.

Sjögren E. (2006), Reasonable drugs: Making decisions with ambiguous knowledge. Stockholm: EFI.

Slater D. (2002), ‘From calculation to alienation: Disentangling economic abstractions’, Economy and Society, 31(2): 234–249.

Thévenot L. (2001), ‘Organized complexity: Conventions of coordination and the composition of economic arrangements’, European Journal of Social Theory, 4(4): 405–425.

Zelizer V. (2005), The purchase of intimacy. Princeton: Princeton University Press.